Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney disease drug study: will empagliflozin change mineral balance?

NCT ID NCT06435858

Recruiting now Knowledge-focused Sponsor: Cantonal Hospital Graubuenden Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 36 times

Summary

This study looks at how Empagliflozin, a diabetes drug, affects calcium, phosphate, and magnesium levels in people with autosomal dominant polycystic kidney disease (ADPKD). About 40 adults will take either the drug or a placebo for 2 weeks, then switch. The goal is to understand how the kidneys handle these minerals, not to treat the disease itself.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cantonal Hospital Graubuenden

    RECRUITING

    Chur, Kanton Graubünden, 7000, Switzerland

    Contact

    Contact Email: •••••@•••••

  • University Hospital Zurich, Division of Nephrology

    RECRUITING

    Zurich, Canton of Zurich, 8091, Switzerland

    Contact

Conditions

Explore the condition pages connected to this study.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE